Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Diana Libster is active.

Publication


Featured researches published by Diana Libster.


American Journal of Hematology | 2012

A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved.

Eldad J. Dann; Zeev Blumenfeld; Rachel Bar-Shalom; Irit Avivi; Menachem Ben-Shachar; Odelia Goor; Diana Libster; Diana Gaitini; Jacob M. Rowe; Ron Epelbaum

Therapy of Hodgkin lymphoma (HL) is designed to prolong survival and minimize toxicity. A total of 124 patients with newly diagnosed HL and adverse prognostic factors were prospectively studied between July, 1999 and August, 2005. Patients with early unfavorable and advanced disease were eligible for the study. Patients were assigned to therapy based on international prognostic score (IPS). Those with IPS ≥ 3 received three cycles of escalated BEACOPP (EB). All others received two cycles of standard BEACOPP (SB). Subsequent therapy was prospectively assigned according to early interim GA67 or positron emission tomography (PET)/computerized tomography (CT). Four cycles of EB or SB were administered following a positive or negative scan, respectively. Complete remission rate, 10‐year progression free (PFS), and overall survival (OS) were 97, 87, and 88%, respectively, at a median follow‐up of 89 months (5–144). PFS and OS were similar in both groups. Fertility status was assessed in 38 females aged <40 years; 94% of females younger than 40 years preserved their cyclic ovarian function. Nineteen conceived during follow‐up for 30 pregnancies, delivering 24 babies. Deliveries were reported up to 7 years from diagnosis. Predictive value of negative interim Ga67 or PET/CT was 87 and 93%, respectively. Six cycles of tailored BEACOPP, for patients with adverse prognostic factors, provide encouraging long‐term PFS and OS, and fertility is preserved in most females. Am. J. Hematol. 2012.


Annals of Surgical Oncology | 2006

Bleeding, Obstruction, and Perforation in a Series of Patients With Aggressive Gastric Lymphoma Treated With Primary Chemotherapy

Galia Spectre; Diana Libster; Sigal Grisariu; Nael Da’as; Dina Ben Yehuda; Zvi Gimmon; Ora Paltiel

BackgroundThe management of patients with gastric lymphoma has evolved, with a shift toward nonsurgical treatment. The rates of surgical complications in patients receiving chemotherapy have been insufficiently studied. The objective of this study was to assess the frequency of bleeding, perforation, and gastric outlet obstruction in patients who received chemotherapy as primary treatment for gastric diffuse large B cell lymphoma (DLBCL).MethodsWe reviewed files of all patients with gastric DLBCL who were diagnosed and treated primarily with chemotherapy in our hospital between 1990 and 2005.ResultsEighteen (25%) of 73 patients experienced surgical complications, of whom 6 (8%) underwent surgery. Eight patients (11%), six with active lymphoma, experienced gastric bleeding; one required gastrectomy. Eight patients (11%) developed gastric outlet obstruction, of whom three were treated conservatively, three required surgery, one stopped treatment, and one received further chemotherapy. Six of the eight patients had no evidence of active lymphoma at the time of obstruction. Two additional patients underwent gastrectomy due to resistant or relapsed disease. Gastric perforation was not observed. Median survival was 90 months for the entire series, 94 months for patients with gastric outlet obstruction, and 11.5 months for patients with gastric bleeding.ConclusionsGiven the rate of surgical complications, especially gastric bleeding and gastric outlet obstruction, there is still an important role for the surgical consultant in the treatment of patients with gastric DLBCL receiving chemotherapy. Gastric perforation, although frequently cited as a complication, is in fact rarely observed.


Leukemia & Lymphoma | 2003

Primary ALK positive anaplastic large cell lymphoma of the pancreas

Yossi Cohen; Diana Libster; Gail Amir; Nurith Hiller; Nael Da'as; Dina Ben Yehuda; Aaron Polliack

Here we present an unusual case of anaplastic lymphoma kinase positive anaplastic large cell lymphoma (ALCL), appearing as a primary tumor of the pancreas which invaded into the adjacent duodenal wall, causing upper gastrointestinal bleeding. After complete resection of the tumor (Whipples operation), the patient received 4 cycles of CHOP chemotherapy. Currently, 2 years after diagnosis the patient still remains lymphoma free. Primary ALCL of the pancreas is very rare and has only been reported on one previous occasion. Nevertheless, lymphoma should be considered in the differential diagnosis of pancreatic tumors and an attempt to obtain tissue diagnosis is always necessary before continuing with radical surgery, especially in young patients.


Leukemia & Lymphoma | 2005

Allergic reaction to chlorambucil in chronic lymphocytic leukemia presenting with fever and lymphadenopathy

Mark Levin; Diana Libster

Chronic lymphocytic leukemia (CLL) is commonly treated with the alkylating agent chlorambucil. Allergic reactions to this chemotherapy are rare. Previous reports include urticaria, angioedema, rashes, toxic epidermal necrolysis, drug fever and one case of immune hemolytic anemia. We report 2 cases that had the identical symptoms of acute onset of high fever and progressive lymphadenopathy. These symptoms disappeared with conservative management. Neither of the patients were treated for infection or disease progression. When the patients were rechallenged with chlorambucil, identical reactions recurred. There was no cross-reactivity with the alkylating agent cyclophosphamide or other types of chemotherapy. This type of reaction to chlorambucil has not been described previously. It is important to recognize this as an allergic reaction. These reactions could be confused with the onset of infection, progression of disease or even a Richters transformation.


European Journal of Haematology | 2018

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

Marjorie Pick; Vladimir Vainstein; Neta Goldschmidt; David Lavie; Diana Libster; Alexander Gural; Sigal Grisariu; Batia Avni; Dina Ben Yehuda; Moshe E. Gatt

Daratumumab is a promising new antimyeloma agent. We report a single center “real‐world” series of multiple myeloma (MM) and amyloidosis (AL) patients treated with daratumumab.


American Journal of Hematology | 2017

Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy

Adir Shaulov; Chezi Ganzel; Noam Benyamini; Yossef Barshay; Neta Goldschmidt; David Lavie; Diana Libster; Alex Gural; Batia Avni; Moshe E. Gatt

Multiple myeloma (MM) and primary systemic light chain amyloidosis (AL) are both chronic plasma cell dyscrasias with different clinical expression but limited treatment options for relapsed refractory disease. We report the effect of the addition of clarithromycin on 31 MM and 17 AL with relapsed or refractory disease who had an insufficient response or disease progression while on an IMiD based therapy. In this high risk population, hematological response was reported in 48% of MM patients and 94% of AL patients. Responses were reported early in both groups (median 35 days) and were more sustained in AL patients. Adverse events were common and included mostly grade 1–2 fatigue, infections and abdominal discomfort. Cytopenias were common and cardiac complications were rare in both MM and AL patients. Clarithromycin‐IMiD combination therapy appears to be both effective and safe in progressive MM and primarily in AL patients, although a prospective clinical trial is warranted to validate these results. Am. J. Hematol. 92:131–135, 2017.


Blood | 2006

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome

Eldad J. Dann; Rachel Bar-Shalom; Ada Tamir; Nissim Haim; Menachem Ben-Shachar; Irit Avivi; Tzila Zuckerman; Mark Kirschbaum; Odelia Goor; Diana Libster; Jacob M. Rowe; Ron Epelbaum


Journal of The American Academy of Dermatology | 2007

Evidence for clinical and genetic heterogeneity in hereditary benign telangiectasia.

Vered Molho-Pessach; Ziad Agha; Diana Libster; Israela Lerer; Ayala Burger; Saleh Jaber; Dvorah Abeliovich; Abraham Zlotogorski


Cancer Chemotherapy and Pharmacology | 2016

Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy

Neta Goldschmidt; Geffen Kleinstern; Marina Orevi; Ora Paltiel; Dina Ben-Yehuda; Alex Gural; Diana Libster; David Lavie; Moshe E. Gatt


Blood | 2009

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved.

Eldad J. Dann; Rachel Bar-Shalom; Ada Tamir; Menachem Ben-Shachar; Irit Avivi; Tsila Zuckerman; Nuhad Haddad; Hanna Rosenbaum; Riva Fineman; Odelia Goor; Diana Libster; Zeev Blumenfeld; Jacob M. Rowe; Ron Epelbaum

Collaboration


Dive into the Diana Libster's collaboration.

Top Co-Authors

Avatar

David Lavie

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Eldad J. Dann

Rambam Health Care Campus

View shared research outputs
Top Co-Authors

Avatar

Moshe E. Gatt

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Neta Goldschmidt

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Odelia Goor

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Irit Avivi

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jacob M. Rowe

Shaare Zedek Medical Center

View shared research outputs
Top Co-Authors

Avatar

Menachem Ben-Shachar

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Rachel Bar-Shalom

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Ron Epelbaum

Technion – Israel Institute of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge